Background
Methods
Cohort characteristics
Patients, n | 1027 |
Median age, years (range) | 64 (30–85) |
Patient gender | n (%) |
Male | 734 (71) |
Female | 293 (29) |
Histology | |
ADC | 498 (48) |
SqCC | 424 (41) |
ADSqCC | 44 (4) |
LC | 51 (5) |
PC | 10 (1) |
TNM-Classification | |
pT1a | 84 (8) |
pT1b | 114 (11) |
pT2a | 484 (47) |
pT2b | 170 (17) |
pT3 | 155 (15) |
pT4 | 20 (2) |
pN0 | 503 (49) |
pN1 | 244 (24) |
pN2 | 249 (24) |
pN3 | 6 (1) |
pNX | 25 (2) |
pM1 | 25 (2) |
pM0 | 1002 (98) |
Clinical stage | |
IA | 133 (13) |
IB | 255 (25) |
IIA | 209 (20) |
IIB | 105 (10) |
IIIA | 286 (28) |
IIIB | 14 (1) |
IV | 25 (2) |
Immunohistochemistry
Antibody | Company | Clone | Pretreatment | Buffer incubation time (min) | Antibody incubation time (min) | Dilution |
---|---|---|---|---|---|---|
CK5/6 | Dako | D5/16 B4 | Tris/Borat/EDTA, pH 9 | 56 | 24 | 1:50 |
HMB45 | Dako | HMB45 | Tris/Borat/EDTA, pH 8.4 | 64 | 24 | 1:75 |
MelanA | Ventana | A103 | Tris/Borat/EDTA, pH 8.4 | 64 | 24 | RTU |
SOX10 | Cell Marque | EP268 | Tris/Borat/EDTA, pH 8.4 | 48 | 24 | 1:100 |
Napsin A | Novocastra | IP64 | Tris/Borat/EDTA, pH 6 | 32 | 24 | 1:400 |
p63 | DCS Immunoline | 4A4 | Tris/Borat/EDTA, pH 6 | 40 | 24 | 1:25 |
TTF-1 | Novocastra | SPT24 | Tris/Borat/EDTA, pH 9 | 56 | 24 | 1:200 |